Author:
Guan Haijing,Shi Yin,Song Jiafang,Cao Mingnan,Sun Aning,Liu Shao,Chang Shi,Zhao Zhigang
Funder
National Natural Science Foundation of China
Reference45 articles.
1. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and europe;Vokinger;JAMA Oncol,2021
2. National value-based pricing negotiation for oncology drugs - lessons from China;Yuan;Nat Rev Clin Oncol,2023
3. Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy;Chen;BMJ,2023
4. Use of health technology assessment in drug reimbursement decisions in China;Chen;BMJ,2023
5. National Healthcare security administration, ministry of human resources and social security of the people's Republic of China on issuing the national reimbursement drug list,2023